This is a phase 2, multicenter, open-label study to evaluate the efficacy of abivertinib with abiraterone in patients with metastatic castration-resistant prostate cancer.

Start Date01 Sep 2025

Sponsor / Collaborator

Sorrento Therapeutics, Inc.

NCT06894511

/ RecruitingPhase 2

A Phase II, Open-label, Multi-Center, Randomized Study Comparing the Combination of Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) and Androgen Receptor Pathway Inhibitor (ARPI) vs. Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in First-line Treatment of Patients With Prostate-Specific Membrane Antigen (PSMA)-Positive Progressive Metastatic Castration Resistant Prostate Cancer (mCRPC)

The purpose of this study is to assess whether the combination of AAA617 (administered for 6 cycles at a dose of 7.4 GBq (200 mCi) +/- 10%) and ARPI improves radiographic progression-free survival (rPFS) or time to death compared to AAA617 alone in PSMA-positive mCRPC patients who were previously treated and progressed on ARPI in the biochemical recurrence (BCR)-non metastatic hormone sensitive prostate cancer (mHSPC), mHSPC, or non-metastatic Castration Resistant Prostate Cancer (nmCRPC) setting and have not previously received a taxane-containing regimen in the castrate resistant prostate cancer (CRPC) setting.

Start Date29 Aug 2025

Sponsor / Collaborator

Novartis Pharmaceuticals Canada, Inc.

100 Clinical Results associated with Abiraterone acetate

100 Translational Medicine associated with Abiraterone acetate

100 Patents (Medical) associated with Abiraterone acetate

3,762

Literatures (Medical) associated with Abiraterone acetate

31 Dec 2025·JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY

Pyridine indole hybrids as novel potent CYP17A1 inhibitors

Article

Author: Wróbel, Tomasz M. ; Pandey, Amit V. ; Grudzińska, Angelika ; Björkling, Fredrik ; Harrington, Jeremiah C. ; du Toit, Therina ; Jørgensen, Flemming Steen ; Yakubu, Jibira ; Sharma, Katyayani

Prostate cancer (PCa) is one of the most prevalent malignancies affecting men worldwide, and androgen deprivation therapy (ADT) is a primary treatment approach. CYP17A1 inhibitors like abiraterone target the steroidogenic pathway to reduce androgen levels, but their clinical efficacy is limited by drug resistance and adverse effects. This study reports the synthesis and evaluation of novel CYP17A1 inhibitors derived from a previously identified hit compound. Several analogs were synthesised, including an unexpected di-cyano derivative, which demonstrated increased potency against CYP17A1 compared to abiraterone. Biological assays revealed that these compounds significantly inhibited CYP17A1 enzymatic activity and altered steroid biosynthesis. Among the newly synthesised inhibitors, compound 11 showed the highest potency (IC₅₀ = 4 nM) and the related compound 14 presented a template for further development. A combined docking and molecular dynamics approach was used to identify the possible target binding modes of the compounds.

01 Sep 2025·Cancer Genetics

Efficacy of pembrolizumab in MSI-high and BRCA-positive castration-resistant prostate cancer

Article

Author: Higa, Keita ; Kanaoka, Sanji ; Nakamura, Kazuyoshi ; Kurokawa, Koichiro ; Watanabe, Koki ; Yamamoto, Satoshi ; Bamba, Hiroki

This report presents a rare case of metastatic castration-resistant prostate cancer (CRPC) in an adult patient characterized by dual molecular alterations: microsatellite instability-high (MSI-H) and a BRCA2 mutation. Despite initial treatment with castration, Abiraterone, and sequential chemotherapy with docetaxel and cabazitaxel, the patient progressed to CRPC. Genetic testing revealed MSI-H and a BRCA2 mutation, prompting pembrolizumab therapy. The treatment led to a dramatic prostate-specific antigen (PSA) reduction . This case underscores the importance of comprehensive genomic profiling for advanced prostate cancer. MSI-H tumors often respond to immune checkpoint inhibitors (ICIs) such as pembrolizumab, while BRCA2 mutations are associated with poly(ADP-ribose) polymerase inhibitors (PARPi) sensitivity. This dual alteration presents therapeutic challenges, as evidenced by pembrolizumab's remarkable efficacy in this patient, highlighting its potential as a treatment option for MSI-H and BRCA-positive CRPC. Moreover, next-generation sequencing (NGS) played a crucial role in identifying actionable biomarkers not detected by earlier BRCA analyses, emphasizing the necessity of thorough genetic testing. Further research is needed to optimize treatment strategies for cases with coexisting MSI-H and BRCA mutations, including exploring the synergistic effects of ICIs and PARP i. This case demonstrates the promise of pembrolizumab and advances the understanding of genetic testing's role in tailoring therapies for complex molecular profiles in prostate cancer.

01 Jul 2025·PHYTOMEDICINE

Erchen Decoction ameliorates the rat model of polycystic ovary syndrome by regulating the steroid biosynthesis pathway

Article

Author: Zhu, Biran ; Zhang, Jinrong ; Huang, Hongming ; Huang, Min ; Zhao, Min ; Xiao, Min ; Wang, Shang ; Jiang, Xiaocui ; Yang, Yong

BACKGROUND:

Polycystic ovary syndrome (PCOS) is a common endocrine and metabolic disorder associated with chronic inflammation and metabolic issues, including insulin resistance, weight gain, and lipid imbalance. It may cause infertility, menstrual irregularities, and increase the likelihood of developing type 2 diabetes, immune system disturbances, and cardiovascular conditions.

OBJECTIVE:

To identify the key components, underlying mechanisms, and therapeutic targets of Erchen decoction (ECD) for treating PCOS.

METHODS:

Abbreviations: Abi group, abiraterone group; AKR, aldo-keto reductase; AMH, anti-Müllerian hormone; BC, betweenness; BP, biological process; BSA, bovine serum albumin; CC, cellular component; CCK-8, cell counting kit-8; Con group, control group; DC, degree centrality; DDA, data-dependent acquisition; DHEA, dehydroepiandrosterone; DHEAS, DHEA sulfate; DHT, dihydrotestosterone; ECD, Erchen decoction; Ecd group, Erchen decoction group; ELISA, enzyme-linked immunosorbent assay; E2, estradiol; FSH, follicle-stimulating hormone; GO, gene ontology; HE, hematoxylin and eosin; H-Ecd group, high-dose Erchen decoction group; HFD, high-fat diet; HSD, hydroxysteroid dehydrogenases; KEGG, Kyoto encyclopedia of genes and genomes; KGN, human granulosa-like tumor cells; LAC, local average connectivity; l-Ecd group, low-dose Erchen decoction group; LH, luteinizing hormone; Met group, metformin (Glucophage) group; MF, molecular function; MIS, Müllerian inhibiting substance; MST, microscale thermophoresis; PCOS model group, PCOS group; PCA, principal component analysis; PCOS, polycystic ovary syndrome; PPI, protein-protein interaction; T, testosterone; TCM, traditional Chinese medicine; Tcm group, traditional Chinese medicine group; UHPLC, ultra-high-performance liquid chromatography Bioinformatics was used to predict the targets of ECD components for treating PCOS. Sprague-Dawley rats were assigned to control (Con) and PCOS model groups. The latter was induced via letrozole (Femara) gavage (1 mg/kg) combined with a high-fat diet. The PCOS group was then subdivided for 28 days of intervention. Body weight was recorded, ovarian morphology was assessed through hematoxylin and eosin staining, and serum hormones were quantified using enzyme-linked immunosorbent assay. Proteomic analyses were performed to examine the underlying mechanisms and potential targets, which were validated using immunofluorescence, western blotting, and RT-qPCR. The pharmacological effects of the key ECD components were confirmed in dihydrotestosterone (DHT)-treated human granulosa KGN cells.

RESULTS:

The body weight of the rats in the Con and high-dose ECD (H-Ecd) groups decreased compared with that in the PCOS group. The H-Ecd and metformin (Glucophage) groups had significantly elevated levels of testosterone (T), luteinizing hormone, anti-Müllerian hormone (AMH), and follicle-stimulating hormone (p < 0.05), whereas the low-dose Ecd (l-Ecd) group showed no significant change. Thirteen blood-entering components and 168 potential therapeutic targets for PCOS were identified. Kyoto encyclopedia of genes and genomes and gene ontology analyses indicated the involvement of the steroid biosynthesis pathway. Principal component analysis revealed notable differences among the Con, H-Ecd, and PCOS groups. Microscale thermophoresis (MST) validated the binding affinities of liquiritin, glycyrrhizic acid, esculetin, and genistein to cytochrome P450 family 17 subfamily A member 1 (CYP17A1) as 5.4, 12.55, 32.8, and 17.6 μM, respectively. Immunofluorescence, western blotting, and RT-qPCR analyses revealed significantly decreased protein expression of CYP17A1 and 11β-hydroxysteroid dehydrogenase type 1 (HSD11B1) (p < 0.01) and significantly increased the expression of aldo-keto reductase family 1 member D1 (AKR1D1) and HSD11B2 in the Con, Met, and H-Ecd groups relative to that in the PCOS group, whereas the l-Ecd group showed no significant difference. The cell counting kit-8 assay demonstrated that abiraterone (100 μM), DHT (100 nM), glycyrrhizic acid (50 μM), liquiritin (600 μM), genistein (300 μM), and esculetin (100 μM) significantly decreased T and AMH levels (p < 0.05). E2 levels recovered significantly (p < 0.05) in the Con, abiraterone (Abi), and traditional Chinese medicine (Tcm) groups compared to that in the DHT group. Western blot analysis indicated a significant reduction in CYP17A1 and HSD11B1 protein expression (p < 0.01) and a significant increase in AKR1D1 and HSD11B2 expression (p < 0.01) in the Con, Abi, and Tcm groups compared to that in the DHT group.

CONCLUSION:

We sought to identify the active constituents of ECD for treating PCOS and found that ECD enhances ovarian function by modulating the expression of CYP17A1, HSD11B1, AKR1D1, and HSD11B2 in the steroid hormone biosynthesis pathway resulting in improved hormone levels and follicular development. These results highlight the potential mechanism underlying ECD-mediated effects for PCOS therapy. Molecular docking validated the interaction of liquiritin, glycyrrhizic acid, esculetin, and genistein with CYP17A1, HSD11B1, AKR1D1, and HSD11B2. These interactions were further confirmed in vitro using MST and validated at the cellular level. Our results offer a scientific foundation for the therapeutic application of ECD in PCOS treatment.

410

News (Medical) associated with Abiraterone acetate

24 Jun 2025

·www.prnewswire.com

CivicaScript® Launches Low-Cost Multiple Sclerosis Treatment to Increase Patient Access, Create Significant Savings

Generic dimethyl fumarate delayed-release capsules are 2nd launch in 3 months Average savings of $4,300/month compared with other generic versions LEHI, Utah, June 24, 2025 /PRNewswire/ -- CivicaScript®, LLC, a nonprofit company dedicated to bringing low-cost generic medicines to U.S. patients, today announced the availability of dimethyl fumarate delayed-release capsules. Dimethyl fumarate delayed-release capsules are indicated for the treatment of relapsing forms of multiple sclerosis (MS) in adults, to include clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease. CivicaScript will offer dimethyl fumarate 240 mg capsules for sale to pharmacies for $47 per bottle of 60 capsules – typically a month's supply. CivicaScript recommends that pharmacies charge patients no more than $68 per bottle (CivicaScript's maximum retail price, or MaxRP TM). CivicaScript's MaxRP policy provides a way for healthcare providers, caregivers, patients and others to compare prices; consumers can confirm they are being charged no more than the MaxRP by scanning the QR code featured on the CivicaScript product label. CivicaScript will offer the 120 mg and 240 mg strengths of dimethyl fumarate capsules for sale. CivicaScript's MaxRP for dimethyl fumarate is about $4,300 per month less than the average claim cost for prescriptions filled at traditional PBM-affiliated pharmacies. 1 It could significantly reduce patients' out-of-pocket costs during the deductible phase of their health insurance, in which they pay full price for their medicines. Savings also could be substantial for patients with co-insurance, which charges them a percentage of their medicines' price. "Today's launch is yet another step in our journey to make necessary medications more affordable for the patients who need them," said CivicaScript President Brent J. Eberle. "We're bringing transparency and affordability to the generic drug market in a sustainable way – saving money for patients and payers and making medicines more accessible." The launch comes on the heels of a report in The New England Journal of Medicine Catalyst that CivicaScript's abiraterone saved consumers 64% and payers 92% when they switched from other versions of the same drug. CivicaScript partners with manufacturers to produce low-cost generic medicines, then works with payers and pharmacies across the country to pass along the cost savings to patients. CivicaScript's business model focuses on transparency and collaboration throughout the value chain from manufacturing through dispensing — with every stakeholder along the way knowing the price of the medicine and driving savings through to the patient. Dimethyl fumarate was chosen by CivicaScript members as a priority generic medicine based on its high list price from other manufacturers and significant patient need for the product. While many generic medicines cost less than brand-name drugs, some high-cost generics are more expensive than they need to be. Numerous studies confirm that medication costs can dictate whether patients ration their prescriptions or even fill them in the first place. About CivicaScript CivicaScript is bringing unprecedented transparency to the drug supply chain to make quality generic medicines affordable and available for everyone. A nonprofit company, CivicaScript is committed to the principles of providing affordable, essential generic medicines to promote the social welfare and health of the community. For more information on the organization and our mission, visit our website. CivicaScript is the Civica, Inc. operating unit for outpatient medications to help drive affordability and price transparency. About dimethyl fumarate For full prescribing information and patient information, including important warnings and precautions, potential adverse reactions and drug interactions, please refer to the Package Insert, available here. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit or call 1-800-FDA-1088. MEDIA CONTACT: Liz Power [email protected] +1 860 501 3849 1 Compared with 2021 average reimbursement rate for all strengths of Dimethyl Fumarate. See Specialty Generic Drugs: A Growing Profit Center for Vertically Integrated Pharmacy Benefit Managers, Federal Trade Commission Second Interim Staff Report, January 2025, at Fig. A2, Table A (pg. 34), available at SOURCE CivicaScript WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

05 Jun 2025

·pipelinereview.com

Acerand Therapeutics Initiates First-in-Human Phase I Clinical Trial of ACE-232, a Novel CYP11A1 Inhibitor for Advanced Prostate Cancer

SHANGHAI, China & INDIANAPOLIS, IN, USA I June 04, 2025 I Acerand Therapeutics, a clinical-stage biotech company focusing on the discovery and development of innovative small-molecule therapies in oncology, today announced the dosing of the first patient in its first-in-human Phase I clinical trial (NCT06801236) of ACE-232, a novel oral inhibitor of CYP11A1. The trial is being conducted in patients with metastatic castration-resistant prostate cancer (mCRPC). This multicenter Phase I study is being conducted in both the United States and China. The study comprises two parts: a dose-escalation phase (Phase IA) and a dose-optimization phase (Phase IB). The primary objectives are to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), as well as preliminary clinical activity of ACE-232, and to determine the recommended Phase II dose (RP2D). Professor Emmanuel Antonarakis, Director of Genitourinary Oncology at Masonic Cancer Center, University of Minnesota, is serving as the global coordinating Principal Investigator for the study. “I would like to congratulate the Acerand team, the research staff, and the first patient for helping us to reach this important milestone,” says Dr. Antonarakis. Preclinical data demonstrated that ACE-232 possesses superior potency, efficacy, and pharmacokinetic properties (flat PK curve and long half-life profile) compared to other investigational CYP11A1 inhibitors, including MK-5684 (Opevesostat, formerly known as ODM-208). ACE-232 showed excellent tolerability in preclinical models, presenting a wide therapeutic window for clinical development. The initiation of this trial marks a significant milestone for Acerand, representing its first clinical study in the United States and highlighting its strategic commitment to the global development of innovative cancer therapies that address major unmet medical needs. About ACE-232 ACE-232 is a highly potent and selective small-molecule inhibitor of CYP11A1, a key adrenal enzyme involved in the first and rate-limiting step of steroid hormone biosynthesis. By targeting CYP11A1, ACE-232 aims to suppress the production of androgens and other steroid hormones, offering a novel therapeutic mechanism for the treatment of androgen-dependent (including enzalutamide or abiraterone-resistant) prostate cancer. About Acerand Therapeutics Acerand Therapeutics is a biotech company dedicated to discovering and developing novel small-molecule therapies for oncology and metabolic diseases. With research and development hubs in Shanghai, China, and Indianapolis, USA, ACE-232 leverages its proprietary innovation platform and operational efficiency to deliver a highly differentiated pipeline of drug candidates from discovery to clinical trials. http://acerand.com/ SOURCE: Acerand Therapeutics

Phase 1

03 Jun 2025

·www.fiercepharma.com

ASCO: J&J's Akeega gives PARP a novel prostate cancer win, but FDA path in patient subset unclear

In castration-sensitive prostate cancer, the Akeega regimen’s magnitude of progression-free survival benefit was notably bigger at 48% in the BRCA-mutated subgroup when compared with the overall trial population. The FDA has already approved PARP inhibitors in certain patients with metastatic castration-resistant prostate cancer (mCRPC). Now, Johnson & Johnson’s Akeega is giving the class a win in castration-sensitive disease, although the drug’s benefit in a patient subgroup remains unclear.In patients with metastatic castration-sensitive prostate cancer (mCSPC) with homologous recombination repair (HRR), Akeega and prednisone significantly reduced the risk of tumor progression or death by 37% versus J&J’s Zytiga and prednisone, according to data shared at the 2025 American Society of Clinical Oncology annual meeting. Akeega is a fixed-dose combination of GSK’s PARP inhibitor Zejula—to which J&J owns prostate cancer rights—and Zytiga.Despite the positive readout from the phase 3 Amplitude trial, saying Akeega has a clear regulatory path ahead in all HRR-mutated mCSPC would be too optimistic.The uncertainty lies in a group of patients without BRCA mutations.Previously, Zejula’s addition to Zytiga and prednisone showed a progression-free survival benefit in HRR-mutated mCRPC in the phase 3 Magnitude trial. But after speaking with the FDA and realizing that the drug was most beneficial in the BRCA-mutated population, J&J filed for—and received—an approval only in that subset of patients. Now, Amplitude is facing the same BRCA/non-BRCA question. Compared with the entire trial population, the Akeega regimen’s magnitude of progression-free survival benefit was notably bigger at 48% in the BRCA-mutated subgroup.“The benefit may be greatest in patients with BRCA alterations,” lead study author Gerhardt Attard, M.D., Ph.D., from University College London, said during a press briefing.The result is still in favor of Akeega in the non-BRCA subgroup, with an improvement of around 20%, Attard noted.“There is efficacy in the non-BRCA subgroup,” Attard said. “It’s heterogeneous, and it’s a number of different smaller gene subgroups.”“You’re going to need to do meta-analysis of multiple different trials to have certainty which subgroup has clear evidence of efficacy.”The non-BRCA subgroup is not small, accounting for 45% of the Amplitude population. Based on the current data, Akeega doesn’t appear to work in patients with the PALB2 mutation, but there are positive trends in other subtypes, Mark Wildgust, Ph.D., vice president of oncology global medical affairs at J&J Innovative Medicine, said in an interview with Fierce Pharma.“Does it have the same magnitude [of benefit as in BRCA]? I do not believe it does,” Wildgust said. “Is there enough there for regulatory approval? Maybe not right now, but maybe in the future. Maybe we have to wait a bit longer to see longer-term follow up and to understand the question.”J&J will have a discussion with global regulators, including the FDA, on whether the Amplitude trial has shown a positive risk-benefit profile in the overall HRR population, Wildgust said.Besides progression-free survival, researchers also identified a positive trend toward improved overall survival in the Akeega arm. However, data here were immature and didn’t meet statistical significance at the current analysis. The preliminary death reduction was 25% in the BRCA-mutated group and 21% in the overall trial population.Editor's Note: The story was updated to clarify the situation around Akeega's mCRPC indication.

Clinical ResultPhase 3ASCO

100 Deals associated with Abiraterone acetate

External Link

KEGG	Wiki	ATC	Drug Bank
D09701	Abiraterone acetate	L02BX03	DB05812

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Prostate Neuroendocrine Carcinoma	Japan	Janssen Pharmaceutical KK	16 Feb 2018
Castration-Resistant Prostatic Cancer	Australia	Janssen-Cilag Pty Ltd.	01 Mar 2012
Hormone-dependent prostate cancer	Australia	Janssen-Cilag Pty Ltd.	01 Mar 2012
Metastatic castration-resistant prostate cancer	United States	Janssen Biotech, Inc.	28 Apr 2011

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Adenocarcinoma of prostate	Phase 3	United States	Tavanta Therapeutics, Inc.	05 May 2021
Adenocarcinoma of prostate	Phase 3	France	Tavanta Therapeutics, Inc.	05 May 2021
Adenocarcinoma of prostate	Phase 3	Hungary	Tavanta Therapeutics, Inc.	05 May 2021
Adenocarcinoma of prostate	Phase 3	Poland	Tavanta Therapeutics, Inc.	05 May 2021
Adenocarcinoma of prostate	Phase 3	Puerto Rico	Tavanta Therapeutics, Inc.	05 May 2021
Adenocarcinoma of prostate	Phase 3	Spain	Tavanta Therapeutics, Inc.	05 May 2021
Adenocarcinoma of prostate	Phase 3	Sweden	Tavanta Therapeutics, Inc.	05 May 2021
Adenocarcinoma of prostate	Phase 3	United Kingdom	Tavanta Therapeutics, Inc.	05 May 2021
Castration-sensitive prostate cancer	Phase 3	United States	Tavanta Therapeutics, Inc.	05 May 2021
Castration-sensitive prostate cancer	Phase 3	France	Tavanta Therapeutics, Inc.	05 May 2021

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04497844 (AMPLITUDE, ASCO2025) Manual	Phase 3	Castration-sensitive prostate cancer Homologous Recombination Deficiency Positive	696	Niraparib (NIRA) and abiraterone acetate plus prednisone (AAP)	xerizpefdu(hqzpmehxbs) = jovllpjtqe absmrsblfj (ysdjqemrso ) Met View more	Positive	30 May 2025
				abiraterone acetate plus prednisone (AAP)	xerizpefdu(hqzpmehxbs) = prfmstwwlw absmrsblfj (ysdjqemrso, 25.8 - NR) Met View more
TriNetX database (ASCO2025)	Not Applicable	Castration-sensitive prostate cancer Prostate-Specific Antigen (PSA)	-	Abiraterone	qxnktikief(curiwcqtha) = fnvdnbkrkk pejxeuuanc (yboluhzsss ) View more	Positive	30 May 2025
				Enzalutamide	qxnktikief(curiwcqtha) = afkthekoes pejxeuuanc (yboluhzsss ) View more
NCT03565835 (ASCO2025)	Phase 2	Metastatic Prostate Carcinoma First line	31	Abiraterone acetate + Prednisone	bfbodksypx(xtfdmgxaxg) = ijczadnnsj ajwlplglzl (gheziuiqbs, 163 - NR) View more	Positive	30 May 2025
ASCO2025	Not Applicable	Metastatic castration-resistant prostate cancer	-	Abiraterone	owisrcyemu(juzvhpbdtn): RR = 1.58 (95% CI, 1.11 - 2.26), P-Value = 0.01	Positive	30 May 2025
				Enzalutamide
Flatiron electronic health records database (ASCO2025)	Not Applicable	Metastatic castration-resistant prostate cancer First line chemotherapy-naïve \| androgen receptor pathway inhibitor (ARPI)-naïve	2,733	Abiraterone acetate	fkegnbyrvy(ugvgivejqb) = riwzajmqeg sarnejysom (ksujfrndcw ) View more	Negative	30 May 2025
				Enzalutamide	fkegnbyrvy(ugvgivejqb) = kykhjhclpe sarnejysom (ksujfrndcw ) View more
AACR2025	Not Applicable	Prostatic Cancer PTEN loss	-	Abiraterone acetate	hleidntpvr(ozckfbseuu) = mice treated with ADT/Abi+capivasertib exhibited increased apoptotic rates azwdrhrehj (ftapwvizzi ) View more	-	28 Apr 2025
				abiraterone acetate (ADT)
NCT03449719 (ARTO, ASCO_GU2025) Manual	Phase 2	Castration-Resistant Prostatic Cancer	157	Abiraterone (BRCA negative)	vldxxxmbeb(sndthtgpxh): HR = 0.86 (95% CI, 0.3 - 2.44), P-Value = 0.773	Positive	13 Feb 2025
				Abiraterone (BRCA positive)
NCT04666129 (ASCO_GU2025) Manual	Phase 1	Advanced Prostate Carcinoma	24	Relugolix 120 mg + Abiraterone 1000 mg + prednisone 5 mg/methylprednisolone 4 mg (Part 1)	gsawcfsbun(dmeihumlki) = qloczvbyim bulcuwavqo (uufmsqltoe, 3.2) View more	Positive	13 Feb 2025
				Relugolix 240 mg + Apalutamide 240 mg	gsawcfsbun(dmeihumlki) = ooafvfglwg bulcuwavqo (uufmsqltoe, 8.0) View more
ASCO_GU2025 Manual	Not Applicable	Castration-sensitive prostate cancer Prostate specific antigen	363	Apalutamide (APA)	cueqjkzbjo(ytsziqcvnb) = jgfwmmouuy yrvkvemcpp (wxzddvfkfk ) View more	Positive	13 Feb 2025
				Abiraterone acetate (ABI)	cueqjkzbjo(ytsziqcvnb) = eazfqubjhn yrvkvemcpp (wxzddvfkfk ) View more
NCT04194554 (ASCLEPIuS, ASCO_GU2025) Manual	Phase 1/2	Prostatic Cancer	54	Abiraterone acetate + Leuprolide + Niraparib	wkrzevlpam(kzqpohzcit) = unifgwcxgv pmfxqhsybg (pwlhooehms ) View more	Positive	13 Feb 2025

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Abiraterone acetate

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation